SCHEMBL13798680

SCHEMBL13798680

CSc1nc(Cl)c2c(C#N)cn(C)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSP90AB1 P08238 8/20 0.37
KCNH2 Q12809 2/20 0.37
CHUK O15111 1/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA7 P43166 3/20 0.33
CA13 Q8N1Q1 3/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 2/20 0.31
IMPDH2 P12268 1/20 0.31
HSP90AA1 P07900 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13798687 0.77 CYP1A2 (0.30) CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL2562784 0.73 CYP1A2 (0.33) CYP1A2CYP2C9CYP2C19KMT2AHSP90AB1
SCHEMBL13798686 0.72 KMT2A (0.37) CYP1A2CYP2C9CYP2C19KMT2AKDM4E
SCHEMBL14421907 0.72 CHUK (0.61) CYP1A2CYP2C9CYP2C19KMT2AHSP90AB1
SCHEMBL13798685 0.71 PIM1 (0.34) KMT2AKDM4ELMNA
SCHEMBL31279583 0.69 KMT2A (0.42) CYP1A2CYP2C9CYP2C19KMT2ACA1
SCHEMBL440008 0.69 KMT2A (0.42) CYP1A2CYP2C9CYP2C19KMT2ACA1
SCHEMBL31153817 0.69 CDK2 (0.46) KMT2AKDM4EALDH1A1LMNAGAA
SCHEMBL2132489 0.66 KMT2A (0.60) CYP1A2CYP2C9CYP2C19KMT2ACA1
SCHEMBL31714743 0.66 HTT (0.40) CYP1A2CYP2C9CYP2C19KMT2AHSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors VERNALIS (R&D) LTD. (GB) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163490-A1 Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors HSP90AA1, HSP90AB1, RAF1 CYP1A2 1056/4885CYP2C9 2665/4885CYP2C19 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.